Cardiovascular complications of treatment for prostate cancer
Prostate cancer, an androgen-dependent disease, is one of the leading causes of mortality in men. It can present as localised disease, locally advanced or distant metastatic disease. Treatment options for patients with prostate cancer include surgery, chemotherapy, brachytherapy, radiation therapy and hormonal therapy. There are multiple treatment options for each stage of the disease, but hormone therapy is usually reserved for advanced stages. Cardiovascular disease is the leading cause of death in patients with prostate cancer and both diseases share common risk factors. Hormone therapy improves prognosis in patients with more advanced disease, albeit at the cost of cardiovascular toxicity. Hormone therapy can be achieved with the use of agonists and antagonists of gonadotropin-releasing hormone receptors, androgen receptor blockers and enzyme inhibitors of androgen synthesis. Drug-specific cardiotoxicity caused by treatments for prostate cancer has not been fully elucidated. Cardiovascular disease in patients with prostate cancer is mainly managed via an ABCDE approach, a strategy to optimise common risk factors. With newer agents improving the prognosis for patients with prostate cancer, cardiovascular toxicity will have a greater impact on the outcomes of these patients. This article reviews cardiovascular risks associated with therapy for prostate cancer with a focus on hormonal therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:83 |
|---|---|
| Enthalten in: |
British journal of hospital medicine (London, England : 2005) - 83(2022), 11 vom: 02. Nov., Seite 1-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferreira, Vera Vaz [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Abiraterone |
|---|
| Anmerkungen: |
Date Completed 05.12.2022 Date Revised 05.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.12968/hmed.2022.0334 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349667268 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349667268 | ||
| 003 | DE-627 | ||
| 005 | 20231226043156.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.12968/hmed.2022.0334 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1165.xml |
| 035 | |a (DE-627)NLM349667268 | ||
| 035 | |a (NLM)36454073 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferreira, Vera Vaz |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cardiovascular complications of treatment for prostate cancer |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.12.2022 | ||
| 500 | |a Date Revised 05.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Prostate cancer, an androgen-dependent disease, is one of the leading causes of mortality in men. It can present as localised disease, locally advanced or distant metastatic disease. Treatment options for patients with prostate cancer include surgery, chemotherapy, brachytherapy, radiation therapy and hormonal therapy. There are multiple treatment options for each stage of the disease, but hormone therapy is usually reserved for advanced stages. Cardiovascular disease is the leading cause of death in patients with prostate cancer and both diseases share common risk factors. Hormone therapy improves prognosis in patients with more advanced disease, albeit at the cost of cardiovascular toxicity. Hormone therapy can be achieved with the use of agonists and antagonists of gonadotropin-releasing hormone receptors, androgen receptor blockers and enzyme inhibitors of androgen synthesis. Drug-specific cardiotoxicity caused by treatments for prostate cancer has not been fully elucidated. Cardiovascular disease in patients with prostate cancer is mainly managed via an ABCDE approach, a strategy to optimise common risk factors. With newer agents improving the prognosis for patients with prostate cancer, cardiovascular toxicity will have a greater impact on the outcomes of these patients. This article reviews cardiovascular risks associated with therapy for prostate cancer with a focus on hormonal therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Abiraterone | |
| 650 | 4 | |a Androgen deprivation therapy | |
| 650 | 4 | |a Androgen receptor blockers | |
| 650 | 4 | |a Cardiovascular toxicity | |
| 650 | 4 | |a Prostate cancer | |
| 650 | 7 | |a Androgens |2 NLM | |
| 700 | 1 | |a Ângelo, Inês |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Boban |e verfasserin |4 aut | |
| 700 | 1 | |a Ghosh, Arjun K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t British journal of hospital medicine (London, England : 2005) |d 2005 |g 83(2022), 11 vom: 02. Nov., Seite 1-12 |w (DE-627)NLM157166031 |x 1750-8460 |7 nnns |
| 773 | 1 | 8 | |g volume:83 |g year:2022 |g number:11 |g day:02 |g month:11 |g pages:1-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.12968/hmed.2022.0334 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 83 |j 2022 |e 11 |b 02 |c 11 |h 1-12 | ||